GBC Blog

Next-Gen Sequencing (NGS) Finds Further Clinical Utility in Oncology

One of the plenary sessions at the 2017 meeting of the Association for Molecular Pathology—“High Impact Molecular Diagnostics for Cancer and Inherited Diseases”—was a virtual mini-course in the latest and most useful applications of next-generation sequencing to detect germline and somatic mutations in cancer. Both speakers zeroed in on the clinical utility of their innovative…

Read More

China Races Ahead in Gene-Editing Trials

China, Unhampered by Rules, Races Ahead in Gene-Editing Trials U.S. scientists helped devise the Crispr biotechnology tool. First to test it in humans are Chinese doctors HANGZHOU, China—In a hospital west of Shanghai, Wu Shixiu since March has been trying to treat cancer patients using a promising new gene-editing tool. U.S. scientists helped devise the…

Read More

Federal Policy for the Protection of Human Subjects – Updated “Common Rule”

The U.S. Department of Health and Human Services and 15 other federal departments and agencies have announced an Interim Final Rule (IFR) that delays by six months the effective date and general compliance date of the revisions to the “Federal Policy for the Protection of Human Subjects” (also known as the Common Rule) originally published…

Read More

How a New Test Could Solve a Costly Problem

A molecular diagnostics company wants to expand its new cartridge-based platform to help orthopedic surgeons make more informed care decisions for patients with a potential joint infection. Curetis is currently expecting an FDA decision on its new cartridge-based diagnostic platform, the Unyvero system, for lower respiratory infections. The company is also collecting samples to pursue…

Read More

Liquid Biopsy Test Shows Promise for Detecting Early-Stage Colorectal Cancer

“Screening for colorectal cancer can be life-saving, but Americans still lag behind Federal government screening goals because current screening options can be inconvenient and uncomfortable for patients. Though this research needs more investigation, a simple, accurate blood test could help increase screening rates, which could ultimately improve detection of colorectal cancers at earlier stages when…

Read More

2020 is the New Hottest Date in Genomics

Year 2020 has been set as the delivery date for 500,000 whole exome sequences from the UK Biobank cohorts. A consortium of six drug companies will turn UK Biobank into the world’s single biggest concentration of genetic and health data anywhere, giving scientists and drug companies a powerful tool for understanding diseases. Biobank is a…

Read More

Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology

– Inked new collaboration and commercialization deals with MGI to leverage Curetis´ sample preparation technology – Enabling short-term commercialization of NGS-based molecular microbiology Amsterdam, the Netherlands, and Holzgerlingen, Germany, January 10, 2018; published at 01:00 am EST — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions,…

Read More

Dr. Robert W. Day – Fed Hutchinson Director and Epigenomics CMO

Originally published January 7, 2018 at 5:43 pm Dr. Robert Day, former director of the Fred Hutchinson Cancer Center who brought the campus to South Lake Union, has died at home. Dr. Robert Day, who led the Fred Hutchinson Cancer Center for 16 years and spent much of his retirement working on public-health issues, died…

Read More

Key Tips for Diagnostics in 2018 and Beyond: Development Success in the Evolving US and EU Landscape

TORONTO, ON–(Marketwired – November 29, 2017) – In an upcoming webinar hosted by Xtalks on Thursday, December 14, 2017, leading diagnostics specialty CRO Health Decisions will introduce guest speakers Gail Radcliffe, Ph.D., President of Radcliffe Consulting Inc. and a member of the Health Decisions Scientific Advisory Board, and Jessica Kappes, MBA, MT, CCRA, Health Decisions Project…

Read More

Epigenomics AG Announces Recent Payment Decision by CMS

21. NOVEMBER 2017.   Berlin (Germany) and Germantown, MD (U.S.A.), November 21, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) announced the Centers of Medicare & Medicaid Services(CMS) has changed their pricing determination for Epi proColon®, the first and only FDA-approved blood-based test for colorectal cancer (CRC) screening. In its recently published final payment…

Read More